Suppr超能文献

酰基辅酶A硫酯酶8(ACOT8)是乳腺癌中预后不良的生物标志物。

Acyl-CoA Thioesterase 8 (ACOT8) is a Poor Prognostic Biomarker in Breast Cancer.

作者信息

Wang Ziyun, Wang Hua

机构信息

Department of Breast and Thyroid Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China.

出版信息

Pharmgenomics Pers Med. 2024 Aug 22;17:403-421. doi: 10.2147/PGPM.S459762. eCollection 2024.

Abstract

PURPOSE

This study aimed to investigate the expression of Acyl-CoA thioesterase 8 (ACOT8) in breast cancer (BC) and its association with clinicopathological characteristics, patient survival, and immune infiltration.

METHODS

We conducted a comprehensive analysis of ACOT8 mRNA differential expression across various cancer types, followed by survival analysis. We focused on BC, where ACOT8 expression was evaluated at both the mRNA and protein levels using online databases, qRT-PCR, and immunohistochemistry. Associations between ACOT8 expression and clinicopathological parameters were assessed using different databases. Additionally, we investigated the prognostic significance of ACOT8 in BC patients by analyzing various cohorts and databases. Furthermore, we predicted a potential signaling pathway and identified miR-1-3p as a possible upstream regulator of ACOT8. Finally, the relationship between ACOT8 and immune system infiltration, as well as immune checkpoint molecules, was examined.

RESULTS

Our findings demonstrated upregulated ACOT8 mRNA and protein levels in BC. Elevated ACOT8 expression correlated positively with various clinicopathological characteristics, indicating an unfavorable prognosis for patients. Functional enrichment analysis suggested ACOT8 involvement in lipid metabolism, mitochondrial components, and ribosomal functions. Moreover, we identified connections between ACOT8 and immune system markers, immune cell infiltration, and immune checkpoints.

CONCLUSION

This study provides compelling evidence for ACOT8 upregulation in BC and its association with clinicopathological features and patient outcomes. Additionally, our findings suggest that targeting ACOT8 and immune checkpoints might enhance the effectiveness of immunotherapy in BC patients.

摘要

目的

本研究旨在调查酰基辅酶A硫酯酶8(ACOT8)在乳腺癌(BC)中的表达及其与临床病理特征、患者生存及免疫浸润的关系。

方法

我们对多种癌症类型中ACOT8 mRNA的差异表达进行了全面分析,随后进行了生存分析。我们重点关注乳腺癌,通过在线数据库、qRT-PCR和免疫组织化学在mRNA和蛋白质水平评估ACOT8的表达。使用不同数据库评估ACOT8表达与临床病理参数之间的关联。此外,我们通过分析不同队列和数据库研究了ACOT8在乳腺癌患者中的预后意义。此外,我们预测了一条潜在的信号通路,并确定miR-1-3p为ACOT8可能的上游调节因子。最后,研究了ACOT8与免疫系统浸润以及免疫检查点分子之间的关系。

结果

我们的研究结果表明乳腺癌中ACOT8 mRNA和蛋白质水平上调。ACOT8表达升高与多种临床病理特征呈正相关,提示患者预后不良。功能富集分析表明ACOT8参与脂质代谢、线粒体成分和核糖体功能。此外,我们确定了ACOT8与免疫系统标志物、免疫细胞浸润和免疫检查点之间的联系。

结论

本研究为乳腺癌中ACOT8上调及其与临床病理特征和患者结局的关联提供了有力证据。此外,我们的研究结果表明,靶向ACOT8和免疫检查点可能会提高乳腺癌患者免疫治疗的有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1805/11346483/6454edd34f8d/PGPM-17-403-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验